Grafil
Generic Name
Filgrastim
Manufacturer
General Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| grafil 300 mcg injection | ৳ 1,200.00 | N/A |
Description
Overview of the medicine
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of neutrophils in patients undergoing chemotherapy or with certain blood disorders. It helps reduce the risk of infection by increasing the number of white blood cells.
Uses & Indications
Dosage
Adults
Chemotherapy-induced neutropenia: 5 mcg/kg/day SC or IV, initiated ≥24 hours after chemotherapy. Bone marrow transplant: 10 mcg/kg/day IV over 4-24 hours or SC, initiated ≥24 hours after chemotherapy. Severe chronic neutropenia: 5-10 mcg/kg/day SC, adjusted based on neutrophil count.
Elderly
No specific dosage adjustment is usually needed; dosage should be based on the patient's individual condition and response.
Renal_impairment
No specific dosage adjustment is routinely required, but close monitoring is recommended.
How to Take
Administered by subcutaneous injection or intravenous infusion. Do not shake the syringe or vial, as shaking may denature the glycoprotein.
Mechanism of Action
Filgrastim binds to specific G-CSF receptors on hematopoietic stem cells, stimulating proliferation, differentiation, and functional activation of granulocytes (primarily neutrophils). This leads to increased production and release of neutrophils from the bone marrow.
Pharmacokinetics
Onset
Neutrophil count increase typically within 2-5 days.
Excretion
Primarily excreted by the kidney; clearance increases with higher neutrophil counts.
Half life
Approximately 3.5 hours after SC or IV administration.
Absorption
Subcutaneous (SC) administration leads to peak serum concentrations within 3-8 hours. Bioavailability is approximately 60-70%. Intravenous (IV) administration results in immediate and complete bioavailability.
Metabolism
Primarily metabolized by the kidney through proteolytic degradation.
Side Effects
Contraindications
- •Known hypersensitivity to filgrastim, E. coli-derived proteins, or any component of the product.
- •Patients with severe chronic neutropenia who have abnormal cytogenetics.
Drug Interactions
Lithium
May potentiate the myeloproliferative effects of filgrastim; use with caution.
Antineoplastic agents
Do not administer filgrastim within 24 hours before or 24 hours after cytotoxic chemotherapy, as rapidly dividing myeloid cells are sensitive to cytotoxic agents.
Storage
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. May be stored at room temperature (up to 25°C/77°F) for a maximum of 24 hours, but discard if not used within this period.
Overdose
The effects of filgrastim overdose have not been fully established. Management involves supportive care and monitoring of complete blood counts, discontinuing the drug once the neutrophil count returns to the desired range.
Pregnancy & Lactation
Pregnancy Category C. Use only if the potential benefit justifies the potential risk to the fetus. It is not known whether filgrastim is excreted in human milk. Exercise caution when administering to a nursing mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months when stored under recommended conditions.
Availability
Hospitals, Pharmacies
Approval Status
Approved
Patent Status
Patent expired for generic
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in